A Randomized, Double-Blind, Placebo-Controlled, Single-Center, Mechanistic Study to Evaluate the Effects of Canagliflozin on Intravascular Volume and Hemodynamics in Subjects With Type 2 Diabetes Mellitus and Heart Failure

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Single-Center, Mechanistic Study to Evaluate the Effects of Canagliflozin on Intravascular Volume and Hemodynamics in Subjects With Type 2 Diabetes Mellitus and Heart Failure

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs Canagliflozin (Primary)
  • Indications Heart failure; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Oct 2017 Last checked against ClinicalTrials.gov record.
    • 10 Oct 2017 Status changed from not yet recruiting to withdrawn prior to enrolment due to IRB review pending IND revision.
    • 29 Aug 2017 Planned initiation date changed from 1 Jul 2017 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top